ReviewMedComm2026
Liver Metastases from Colorectal Cancer: From Pathogenesis to Current Treatment.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains one of the most frequently diagnosed malignancies worldwide, and colorectal cancer liver metastasis (CRLM) represents a major cause of CRC-related mortality. The liver provides a highly specialized environment that can be remodeled into a metastatic niche, where anatomical structure, metabolic properties, and immunological landscape collectively influence tumor cell survival, colonization, and outgrowth. Increasing evidence indicates that CRLM development is driven by dynamic interactions between tumor intrinsic programs and the hepatic tumor microenvironment(TME), involving epithelial plasticity, intercellular communication, stromal remodeling, and immune regulation. However, an integrated understanding that links metastatic initiation, hepatic niche formation, immune escape, and therapeutic intervention remain lacking. This review examines recent advances in the multistage progression of CRLM and discusses how immune tolerance, lymphocyte dysfunction, and suppressive cellular networks contribute to the establishment and maintenance of the CRLM. Finally, we review current clinical management strategies and emerging approaches, immunotherapy, and biomarker-guided precision treatment. By integrating mechanistic insights with clinical perspectives, this review aims to provide a conceptual framework for understanding CRLM progression and to identify potential directions for improving individualized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.